Rodrigo Chan is a Cardiology physician affiliated with Chan Heart Rhythm Institute. OpenAlex indexes 13 publications with 579 citations (h-index 7).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6709 E Southern Ave
Mesa, AZ 852063738
Telephone
480-773-2220Provider last certified this registry record 8 Oct 2025.
Industry payments
47 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BIOTRONIK INC.Program year202527 payments
- Medtronic, Inc.Program year202515 payments
- AOP Health US, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
75.4%Beta blocker17.6%Metoprolol Tartrate32%Carvedilol21%Metoprolol Succinate20%Sotalol18%Propranolol Hcl3%Atenolol2%Nebivolol Hcl2%Propranolol Hcl Er2%Sotalol Af1%Part D<11 patientsCalcium channel blocker11%Nifedipine Er29%Diltiazem 24hr Er (Cd)24%Amlodipine Besylate15%Diltiazem 24hr Er10%Diltiazem Hcl8%Diltiazem 12hr Er4%Cartia Xt3%Tiadylt Er2%Verapamil Er2%Verapamil Hcl1%Diltiazem 24hr Er (La)1%Part D<11 patients+ 20 more classes in this area
Blood & clotting
11.4%Factor Xa inhibitor9.7%Eliquis87%Xarelto13%Part D≥238 patientsP2Y12 inhibitor1.3%Clopidogrel100%Part D≥46 patients+ 2 more classes in this area
Metabolism & gastrointestinal
7.9%GLP-1 receptor agonist3.7%Ozempic64%Mounjaro36%Part D≥63 patientsPotassium supplement1.3%Potassium Chloride100%Part D≥46 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System
Circulation Heart Failure
2020 - Heart Failure Diagnostics Sensor Measurements Change Prior to Heart Failure Decompensation Events
Journal of Cardiac Failure
2017 - Novel echocardiographic prediction of non-response to cardiac resynchronization therapy
Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
2009 - The Effect of Ablation Electrode Length and Catheter Tip to Endocardial Orientation on Radiofrequency Lesion Size in the Canine Right Atrium
Pacing and Clinical Electrophysiology
2002
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”